Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Linde PLC — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.36 (market cap $5.85B), while Linde PLC trades at $481.06 (market cap $223.11B). The key difference: Linde PLC is far larger — about 38.1× Iovance Biotherapeutics Inc. Common Stock's market cap, and Linde PLC pays a 1.32% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Linde PLC for 88 Days on average.
| IOVA | LIN | |
|---|---|---|
Market Cap | $5.85B | $223.11B |
Volume | 14,517,176 | 1,940,149 |
Sector | Health | Basic Materials |
52-Week High | $14.82 | $546.64 |
52-Week Low | $1.81 | $389.38 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $5.78B | $246.22B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LIN trades at $481.70, down 1.68% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings of $4.50 per share, beating estimates, and raised the lower end of its 2026 guidance. Revenue growth is steady, with a net income margin of 20.43% in 2025. Analyst consensus is overwhelmingly positive, with a $557.10 price target. Support is seen near $480, while resistance lies at $486.
Outlook remains favorable due to consistent earnings beats and a record $8.1 billion project backlog. Risks include elevated valuation multiples and margin pressures from higher capital expenditures. The stock offers a dividend yield with a $1.60 payment scheduled for September 2026. Investor sentiment is buoyed by AI-related contract wins, though competition and capex increases warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
